Navigation Links
ClearLight Diagnostics and Researchers at the Indiana University's Melvin and Bren Simon Cancer Center Announce a Collaboration to Profile the Tumor Microenvironment in Patients with Breast Cancer
Date:5/3/2017

SUNNYVALE, Calif., May 3, 2017 /PRNewswire/ -- ClearLight Diagnostics, LLC, (ClearLight) a developer of a next generation tissue processing and 3D imaging platform, announced today that it has signed a collaboration agreement with the Indiana University Melvin and Bren Simon Cancer Center to study the tumor microenvironment in patients with breast cancer. Working with researchers in the Department of Pathology and Clinical Medicine, ClearLight will use the CLARITY method and 3D imaging to map key aspects of the microenvironment of breast cancer tumors.  Using CLARITY, the heterogeneity of both the tumor and the tumor microenvironment can be better understood in solid tumors due to the elucidation of 3D spatial information versus analysis by standard 2D, thin section tissue processing methods. Profiling 3D aspects of breast cancer tumor tissue is particularly valuable relative to the analysis of tumor-infiltrating lymphocytes (TILs) and their clinical value for patients. Several independent studies have demonstrated that TILs are prognostic in breast cancer, with the potential to demonstrate relevance for response to immune-checkpoint inhibitor therapy. Phenotyping TILs and characterizing the spatial relationships of the vasculature as well as key standard of care tumor biomarkers will create a new knowledge base for capturing the heterogeneity of breast cancer tissue.

"We are very fortunate to be working with a world-class team of investigators who have made practice changing contributions to the field of translational cancer research as well as clinical treatment practice," said Laurie Goodman, Ph.D., Chief Scientific Officer at ClearLight Diagnostics.  "This collaboration is key to the advancement of the analytic and eventual clinical development of our platform."

"We are excited to apply this revolutionary technology to a variety of preclinical and clinical models of breast cancer that are important to our clinical research program. These will greatly assist developing novel biomarker based therapies for our patients," said Sunil Badve, MD, Joshua Edwards Professor of Pathology & Laboratory Medicine and Director of the Translational Genomics Core.  

The collaboration between ClearLight and Indiana University School of Medicine demonstrates a commitment to convert research discovery to clinical application.

About ClearLight Diagnostics

ClearLight Diagnostics is a technology development company focused on the discovery, development, and commercialization of innovative technologies to significantly improve the diagnosis and treatment of a wide range of diseases with an initial focus in oncology. Founded by Karl Deisseroth MD, PhD, ClearLight is developing a product platform based on the CLARITY lipid-clearing technique developed by Dr. Deisseroth and colleagues at Stanford University. This technique enables the transformation of tissue into a nanoporous, hydrogel-hybridized form that is crosslinked to a three-dimensional network of hydrophilic polymers. The process produces a fully assembled, intact tissue, which is permeable to macromolecules and optically transparent, thus allowing for robust three-dimensional imaging of subcellular components (DNA, RNA and protein) and heterogeneous cellular interactions within the tumor microenvironment.  This technology, paired with the development of a tissue imaging platform that includes the revolutionary microscopy method, COLM (CLARITY Optimized Light-sheet Microscopy) will enable unprecedented depth and acceleration of image collection from lipid-cleared samples interrogated with biomolecules.  Visit www.clearlightdx.com.

Contact:

Laurie Goodman, PhD

5104705042

157798@email4pr.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/clearlight-diagnostics-and-researchers-at-the-indiana-universitys-melvin-and-bren-simon-cancer-center-announce-a-collaboration-to-profile-the-tumor-microenvironment-in-patients-with-breast-cancer-300450540.html


'/>"/>
SOURCE Clearlight Diagnostics, LLC
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. DMG is Proud to Announce that CD Diagnostics will be Featured in an Upcoming Episode of Health Heroes
2. Boston Heart Diagnostics Awarded $450,000 in Tax Incentives from the Massachusetts Life Sciences Center
3. PrimeraDx to Co-Develop Companion Diagnostics with Quest Diagnostics
4. Dominion Diagnostics to Sponsor 2013 Addiction Professional Panel Series as Thought Leadership Partner
5. MGC Diagnostics Corporation Announces Special Cash Dividend and Extension of Stock Repurchase Program
6. Slone Partners CEO & President Speak about Hiring Challenges in Molecular Diagnostics at Executive War College 2013
7. Advanced Animal Diagnostics Raises $6 Million for On-farm Diagnostics
8. Isothermal Nucleic Acid Amplification Technologies Market 2012-2017: Molecular Diagnostics, Infectious Disease Testing, Blood Screening, Cancer Research, Rapid Testing
9. TrueVision® 3D Surgical and i-Optics Announce Collaboration to Integrate Diagnostics and Computer-Guidance in Cataract Surgery
10. Exosome Diagnostics Names Kapil Dhingra Chairman of the Board of Directors
11. BioConference Live Lands CMO of Roche Diagnostics and Other High Level Speakers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2019)... ... ... 16.2 hands, Atlas is on the large side for a Quarter Horse. He and ... activities. When loping around a corner in late 2017, Atlas tripped and partially tore ... being able to walk. Fortunately Atlas’ owner, Kelly, sought the opinion of her veterinarian, ...
(Date:5/4/2019)... PINE BROOK, N.J. (PRWEB) , ... May 03, ... ... visual electrophysiology, announces the release of the Diopsys® ffERG/Photopic Negative Response ... signs of glaucoma. , By 2050, it is estimated that 6.3 million Americans ...
(Date:5/2/2019)... ... May 02, 2019 , ... Stay on top of current ... and food industries. Access to all webinars is free, so be sure to register ... field! , Visit http://www.xtalks.com to see our upcoming webinars: , CLINICAL TRIALS ...
(Date:4/25/2019)... ... April 23, 2019 , ... Frank is an albino, deaf Great Dane. His owners ... him due to his health issues. Despite his hearing impairment, he was always an active ... two would play all day, every day. As the two grew, playtime became rougher and ...
Breaking Biology Technology:
(Date:6/24/2019)... ... June 24, 2019 , ... According to the World ... the four most common STDs: chlamydia, gonorrhea, trichomoniasis (or "trich") and syphilis. And that’s ... and bisexual African American men accounted for the largest number of HIV diagnoses (9,807), ...
(Date:6/16/2019)... ... June 14, 2019 , ... Respected periodontist, ... the fifth annual Neodent World Congress. Attended by thousands of dental clinicians from ... advancements in the world of dentistry. The three-day event featured a team of ...
(Date:6/13/2019)... Pa. (PRWEB) , ... June 13, 2019 , ... ... LP , the first organization exclusively serving the end-to-end clinical and ancillary supply ... as well as contract and medical research organizations, today announced it will sponsor ...
Breaking Biology News(10 mins):